We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Serum Omentin-1 and Carotid Atherosclerosis In Non-Diabetic Chronic Kidney Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01701830
Recruitment Status : Unknown
Verified October 2012 by Kocaeli Derince Education and Research Hospital.
Recruitment status was:  Recruiting
First Posted : October 5, 2012
Last Update Posted : October 5, 2012
Sponsor:
Information provided by (Responsible Party):

October 3, 2012
October 5, 2012
October 5, 2012
October 2012
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Serum Omentin-1 and Carotid Atherosclerosis In Non-Diabetic Chronic Kidney Disease
The Relationship Between Serum Omentin-1 and IL-6 and Carotid Atherosclerosis In Non-Diabetic Chronic Kidney Disease
The aim of the study is to evaluate whether a low level of serum omentin-1 is associated with carotid atherosclerosis and mediated by inflammation.
Atherosclerotic cardiovascular disease is markedly increased in chronic kidney disease. There are a lot of risk factor, along with conventional risk factors. Serum onemtin-1 is a adipokine and suggested as a new marker for vascular disease.It has some anti-atherogenic properties. Studies investigating serum omentin-1 level have usually conducted in patients with diabetes mellitus.
Observational
Observational Model: Case Control
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Non-Probability Sample
Department of Nephrology, Check-up clinic
  • Non-diabetic Chronic Kidney Disease
  • Atherosclerosis
Not Provided
  • Case Group
    Patients with chronic kidney disease of stage 3-4.
  • Control group
    30 healthy subject
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
85
May 2013
Not Provided

Inclusion Criteria:

  • between ages of 18 - 65 years old chronic kidney disease of stage 3-4

Exclusion Criteria:

  • Chronic kidney disease of stage 5
  • The history of ischemic cardiovascular disease (myocardial infarction, unstable angina, stroke, peripheral artery disease, or cardiovascular revascularization)
  • Severe heart failure
  • Stage 2 hypertension
  • Diabetes mellitus
  • Corticosteroid therapy
  • Severe hepatic disease
  • Smoking
  • Inflammatory disease
  • Acute infectious disease
  • Malignancy
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
Turkey
 
 
NCT01701830
2012/02
Not Provided
Not Provided
Not Provided
Kocaeli Derince Education and Research Hospital
Kocaeli Derince Education and Research Hospital
Not Provided
Principal Investigator: Erkan SENGUL, MD Kocaeli Derince Education and Training Hospital
Kocaeli Derince Education and Research Hospital
October 2012